Holen Sie sich die Stockscreener-App
571.06
3.05%
16.88
Handel nachbörslich:
571.06
Schlusskurs vom Vortag:
$554.18
Offen:
$560.44
24-Stunden-Volumen:
946.32K
Relative Volume:
0.99
Marktkapitalisierung:
$62.43B
Einnahmen:
$14.20B
Nettoeinkommen (Verlust:
$4.41B
KGV:
14.92
EPS:
38.28
Netto-Cashflow:
$3.54B
1W Leistung:
-0.30%
1M Leistung:
-14.37%
6M Leistung:
-43.70%
1J Leistung:
-36.88%
1-Tages-Spanne:
$555.39
$574.72
1-Wochen-Bereich:
$525.99
$586.03
52-Wochen-Spanne:
$525.99
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Firmenname
Regeneron Pharmaceuticals Inc
Sektor
Branche
Telefon
(914) 847-7000
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Vergleichen Sie REGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
571.06 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.83 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
ARGX
Argen X Se Adr
|
606.39 | 36.98B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.01 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
242.75 | 26.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-09-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Eingeleitet | Bernstein | Outperform |
| 2024-01-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Bestätigt | Oppenheimer | Perform |
| 2023-06-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-23 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2023-01-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-09-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-12-07 | Fortgesetzt | Cowen | Market Perform |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2021-11-05 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-01-25 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-10-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Hochstufung | SunTrust | Hold → Buy |
| 2020-05-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-17 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Eingeleitet | The Benchmark Company | Hold |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-11 | Hochstufung | Argus | Hold → Buy |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-16 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Hold |
| 2019-11-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
Alle ansehen
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Biocon Biologics Secures US Market Entry for Yesafili - Rediff MoneyWiz
Treasurer of the State of North Carolina Lowers Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stake Boosted by FIL Ltd - MarketBeat
Envestnet Asset Management Inc. Raises Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Distillate Capital Partners LLC Buys Shares of 32,141 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN) - Yahoo Finance
FDA Action Alert: Regeneron, Sanofi and Abeona - BioSpace
Bank of Nova Scotia Sells 8,529 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Martingale Asset Management L P Reduces Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Bank of Montreal Can Has $109.18 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
APG Asset Management N.V. Purchases 59,984 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
679 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Coign Capital Advisors LLC - MarketBeat
Heritage Trust Co Purchases Shares of 2,411 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by F M Investments LLC - MarketBeat
Renaissance Technologies LLC Increases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 52-Week LowHere's Why - MarketBeat
Invesco Ltd. Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Wells Fargo & Company MN - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Legal & General Group Plc - MarketBeat
Peapack Gladstone Financial Corp Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Massachusetts Financial Services Co. MA Cuts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Amgen’s Bundling Antitrust Case Against Regeneron Proceeds - USA Herald
Cerity Partners LLC Raises Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Amgen Can't Ditch Regeneron's Bundling Antitrust Suit - Law360
ADAR1 Capital Management LLC Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Russell Investments Group Ltd. Raises Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Citigroup Adjusts Price Target on Regeneron Pharmaceuticals to $600 From $750, Keeps Neutral Rating - MarketScreener
Next Generation Immunotherapies Market Growth Projections - openPR.com
CenterBook Partners LP Trims Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Goldman Sachs Cuts Price Target on Regeneron Pharmaceuticals to $917 From $1,019, Keeps Buy Rating - MarketScreener
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Federated Hermes Inc. - MarketBeat
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies - Benzinga
Regeneron (REGN) Price Target Cut by Guggenheim Prior to Q1 Earnings | REGN Stock News - GuruFocus
Central Retinal Vein Occlusion Therapeutics Market Size in 7MM - openPR.com
Ilmarinen Mutual Pension Insurance Co Buys 3,400 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Guggenheim Adjusts Price Target on Regeneron Pharmaceuticals to $940 From $950, Maintains Buy Rating - MarketScreener
Prostate Cancer Pipeline Analysis and Clinical Trials - openPR.com
May 30th Options Now Available For Regeneron Pharmaceuticals - Nasdaq
Guggenheim cuts Regeneron stock price target to $940, maintains buy By Investing.com - Investing.com India
Guggenheim cuts Regeneron stock price target to $940, maintains buy - Investing.com
Biopharmaceuticals Global Overview Report 2025: Global Market to Reach $698.7 Billion by 2030, Fueled by Specialized Therapies, Such as mAb and Gene Treatments, & a Strong Pipeline - GlobeNewswire Inc.
Grantham Mayo Van Otterloo & Co. LLC Buys 10,982 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Pamalican Asset Management Ltd Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Atopic Dermatitis Pipeline 2025: Therapies Under - openPR.com
Is Regeneron Pharmaceuticals Gaining or Losing Market Support? - Benzinga
Diabetic Retinopathy Market Deep Research Report with Forecast - openPR.com
Morgan Stanley Adjusts PT on Regeneron Pharmaceuticals to $1,081 From $1,150, Keeps Overweight Rating - MarketScreener
HPV16+ Anogenital Cancers Therapeutics Market Size in 7MM - openPR.com
Orion Investment Co Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Bryce Point Capital LLC Buys New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Learn to Evaluate (REGN) using the Charts - news.stocktradersdaily.com
Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):